VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ChinuSFO who wrote (9704)	6/16/1998 9:11:00 AM
From: Frostman	Read Replies (1) of 23519

$1,000 a share? I'm borrowing against it and retiring this morning! (g) This from WSJ on-line, same story, tighter editing. Vivus up 3/16's in pre-open trading, looks good to gap up. Then.....? Frostman ************************Vivus Says Muse Achieves 60% Efficacy Rate In Diabetic Men Dow Jones Newswires MOUNTAIN VIEW, Calif. -- Vivus Inc.'s (VVUS) Muse product achieved a 60% efficacy rate in diabetic men with erectile dysfunction. In a press release Tuesday, Vivus said the treatment was deemed successful when patients completed sexual intercourse at least two times. The study involved 65 diabetic and 165 non-diabetic men with erectile dysfunction who received Muse for six months. The results indicated 60% of the diabetic patients achieved "success" compared with 54% of non-diabetic patients. Vivus said researchers also concluded that Muse appears to be more effective in men over age 50 and perhaps more effective in men with organic risk factors, as opposed to psychological factors. Vivus develops therapeutic systems to treat erectile dysfunction. ************************************************** Thanks Vivus, nice work! How boutcha' FDA?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next